Price to Book Value Chart

View Price to Book Value for BEBE.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Price to Book Value Chart
Start Trial

Historical Price to Book Value Data

View and export this data back to 2026. Start Trial.
Date Value
September 21, 2026 1.196
September 18, 2026 1.196
September 17, 2026 1.196
September 16, 2026 1.196
September 15, 2026 1.196
September 14, 2026 1.198
September 11, 2026 1.195
September 10, 2026 1.189
September 09, 2026 1.189
September 08, 2026 1.189
September 04, 2026 1.189
September 03, 2026 1.189
September 02, 2026 1.189
September 01, 2026 1.189
August 31, 2026 1.189
August 28, 2026 1.189
August 27, 2026 1.190
August 26, 2026 1.190
August 25, 2026 1.196
August 24, 2026 1.196
August 21, 2026 1.190
August 20, 2026 1.192
August 19, 2026 1.192
August 18, 2026 1.192
August 17, 2026 1.192
Date Value
August 14, 2026 1.192
August 13, 2026 1.192
August 12, 2026 1.192
August 11, 2026 1.189
August 10, 2026 1.189
August 07, 2026 1.189
August 06, 2026 1.189
August 05, 2026 1.189
August 04, 2026 1.189
August 03, 2026 1.189
July 31, 2026 1.189
July 30, 2026 1.189
July 29, 2026 1.190
July 28, 2026 1.190
July 27, 2026 1.190
July 24, 2026 1.188
July 23, 2026 1.188
July 22, 2026 1.188
July 21, 2026 1.188
July 20, 2026 1.188
July 17, 2026 1.189
July 16, 2026 1.188
July 15, 2026 1.190
July 14, 2026 1.190
July 13, 2026 1.190

Price to Book Ratio Definition

Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.

Read full definition.

Price to Book Value Range, Past 5 Years

View Price to Book Value Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Price to Book Value Benchmarks

View Price to Book Value Benchmarks
Start Trial
Sanofi 1.432
DBV Technologies SA 3.444
Cellectis SA 3.703
Innate Pharma SA --
Inventiva SA 2.059

Price to Book Value Related Metrics

PE Ratio 70.70
Price 10.04
Earnings Yield 1.41%
Market Cap 200.80M
Normalized PE Ratio 70.70